Access Pharma (ACCP) Launches MuGard Product Website
Posted by Mike Sweeney on Wed, Sep 15, 2010 @ 12:41 PM
Following yesterday's Blog on the first order for MuGard, Access Pharmaceuticals (OTCBB: ACCP) launched a product specific website at www.MuGard.com. The patient- and healthcare professional- focused site is a comprehensive resource offering educational material on oral mucositis, patient analysis, MuGard product and how-to-order information.
In a press release, Frank Jacobucci, VP of Sales and Marketing for Access Pharma stated:
"We are proud to have launched our product website as it resource for patients and healthcare professionals," said Frank Jacobucci, VP of Sales and Marketing for Access Pharmaceuticals, Inc. He continued, "Keeping the patient in mind, we constructed an easy-to-navigate MuGard destination where both patients and doctors can go to learn about oral mucositis, symptoms and the benefit that MuGard provides someone undergoing radiation and chemotherapy for various types of cancers, including head and neck cancers, such as throat cancer. By starting MuGard on the first day of anticancer regimens, as shown in the clinical data, a significant number of patients can significantly reduce the occurrence, duration and severity of oral mucositis. MuGard – first day, every day."
Full Press Release
About MuGard:
MuGard is a novel; ready-to-use mucoadhesive oral wound rinse and coating for the management of oral mucositis, a debilitating side effect of many anticancer treatments. Characterized Up to 40% of all patients receiving chemotherapy develop moderate to severe mucositis, and almost all patients receiving radiation for head and neck cancer and those undergoing stem cell transplantation develop mucositis. Updated clinical practice guidelines for the prevention and treatment of mucositis recommend the use of a preventive oral care regimen as part of routine supportive care along with a therapeutic oral care regimen if mucositis develops. The market for the treatment of oral mucositis is estimated to be in excess of $1 billion world-wide. For more information, visit www.MuGard.com.